Kazia Therapeutics (KZIA) Liabilities and Shareholders Equity (2017 - 2025)
Kazia Therapeutics' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $3.9 million for Q2 2025.
- For Q2 2025, Liabilities and Shareholders Equity fell 72.71% year-over-year to $3.9 million; the TTM value through Jun 2025 reached $62.6 million, down 21.8%, while the annual FY2025 figure was $3.9 million, 72.71% down from the prior year.
- Liabilities and Shareholders Equity reached $3.9 million in Q2 2025 per KZIA's latest filing, down from $14.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $25.7 million in Q2 2022 to a low of $3.9 million in Q2 2025.
- Average Liabilities and Shareholders Equity over 4 years is $15.6 million, with a median of $16.5 million recorded in 2023.
- Peak YoY movement for Liabilities and Shareholders Equity: dropped 24.21% in 2024, then crashed 72.71% in 2025.
- A 4-year view of Liabilities and Shareholders Equity shows it stood at $25.7 million in 2022, then fell by 26.98% to $18.8 million in 2023, then fell by 24.21% to $14.2 million in 2024, then plummeted by 72.71% to $3.9 million in 2025.
- Per Business Quant, the three most recent readings for KZIA's Liabilities and Shareholders Equity are $3.9 million (Q2 2025), $14.2 million (Q2 2024), and $18.8 million (Q2 2023).